A Registry Study to Evaluate the Survival and Long-Term Safety of Subjects Who Previously Received Talimogene Laherparepvec in Amgen or BioVEX-Sponsored Clinical Trials

First published 28/09/2021

Last updated 30/10/2024

EU PAS number:

EUPAS43115

Study

Finalised

Documents

Study protocol

Initial protocol

Protocol-Published talimogene laherparepvec 20120139.pdf

English (820.99 KB - PDF)View document

Study results

20120139 Clinical Study Report Synopsis

English (333.79 KB - PDF)View document

Study report

Other information

Secondary tabs